Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Journal
Journal of hepatology
Journal Volume
76
Journal Issue
4
Pages
862
Date Issued
2022-04
Author(s)
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R
Ducreux, Michel
Kim, Tae-You
Lim, Ho Yeong
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O
Li, Daneng
Verret, Wendy
Ma, Ning
Nicholas, Alan
Wang, Yifan
Li, Lindong
Zhu, Andrew X
Finn, Richard S
Abstract
IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). We present updated data after 12 months of additional follow-up.
Subjects
PD-L1 inhibitor; advanced hepatocellular carcinoma; combination treatment; first-line systemic treatment; overall survival; survival benefit
SDGs
Publisher
ELSEVIER
Type
journal article